READ: Featured Drug Insights: August 2025 - Prime Therapeutics
READ: Featured Drug Insights: August 2025
Your source for all Prime Therapeutics' August 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for August 2025 will keep you informed on what’s trending now and trending clinical topics.
Released Aug. 7, 2025
FDA drug recalls
Sucralfate tablets within expiry
Nostrum is initiating a voluntary recall of Sucralfate Tablets, 1 gram (NDCs 29033-0003-01, 29033-0003-05) for all lots within expiry. The company cannot guarantee that this product will meet intended specifications through the product’s expiration date. Read more about this recall.
Released Aug. 11, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are brensocatib, etuvetidigene autotemcel, onasemnogene abeparvovec and more.
Released Aug. 13, 2025
Expert Clinical Network Insights: August 2025
Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features teprotumumab-trbw (Tepezza).
Released Aug. 14, 2025
FDA Decisions Expected: September 2025
A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers denosumab, bumetanide nasal spray, apitegromab and more.
Released Aug. 15, 2025
Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features Apitegromab, an intravenous, muscle-targeted therapy intended to improve motor functions for patients with spinal muscular atrophy (SMA).
Released Aug. 19, 2025
Featuring commentary by Simone Ndujiuba, PharmD, BCOP on developments in the oncology space, this installment covers a regulatory shift as the US Food and Drug Administration (FDA) removes T-cell (CAR T)-cell therapies from the risk evaluation and mitigation strategy (REMS) program.
Released Aug. 28, 2025
A quartely view of the GLP-1 pipeline and anticipated indications, offering a credible clinical snapshot of what's ahead. See what's coming in the emerging GLP-1 landscape.
Released Aug. 29, 2025
Trending Topics & Drug Approvals: August 2025
We've combined Clinical Highlights and Drug Approvals into this new, monthly publication, which covers the latest specialty and traditional drug approvals. The latest edition features an update on mRNA vaccine development and investments.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.